Epigenetic Analysis of IGF2 in Serous Epithelial Ovarian Tumors
Characteristic | n | Age (Avg) | CTCF-1* | CTCF-6*,† | IGF2 DMR‡ | LOI§ | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Borderline | 5 | 41.4 | 2/2 | 0/5 | 2/3 | 0/2 | ||||||
Early stage (I/II) | 9 | 55.2 | 6/2 | 1/8 | 4/5 | 0/2 | ||||||
Advanced stage (III/IV) | 64 | 60.9 | 37/16 | 28/29 | 14/44 | 5/16 | ||||||
Normal lymphocytes∥ | 43 | N/A | 3/30 | 2/37 | 2/41 | N/A | ||||||
Age at diagnosis (y) | ||||||||||||
≤50 | 17 | 44.9 | 10/5 | 5/11 | 7/10 | 1/3 | ||||||
>50 | 56 | 64.8 | 33/13 | 24/25 | 11/39 | 4/15 | ||||||
Fisher's exact P | 1.00 | 0.27 | 0.21 | 1.00 | ||||||||
Survival (advanced stage) | ||||||||||||
≤3 y postdiagnosis | 30 | 59.7 | 16/6 | 12/13 | 7/20 | 3/7 | ||||||
≥7 y postdiagnosis | 24 | 60.1 | 15/6 | 11/11 | 6/15 | 2/7 | ||||||
Fisher's exact P | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
IGF2 expression | ||||||||||||
Microarray ≤90 | 26 | 57.6 | 11/9 | 5/17 | 10/14 | 4/3 | ||||||
Microarray >90 | 35 | 60.7 | 25/5 | 18/14 | 7/24 | 1/12 | ||||||
Fisher's exact P | 0.05 | 0.02 | 0.15 | 0.03 | ||||||||
Epigenetic features | ||||||||||||
Borderline vs malignant | 0.58¶ | 0.07¶ | 0.61¶ | 1.00¶ | ||||||||
Stage I/II vs III/IV | 1.00¶ | 0.07¶ | 0.24¶ | 1.00¶ | ||||||||
Malignant vs lymphocytes | <0.0001¶ | <0.0001¶ | 0.004¶ | N/A |
Abbreviation: N/A, not applicable.
↵* Number exhibiting hypermethylation/number exhibiting differential methylation.
↵† One sample was not tabulated here because it was hypermethylated at CTCF-6.
↵‡ Number exhibiting hypomethylation/number exhibiting differential methylation.
↵§ Number with loss of IGF2 imprinting/number with maintenance of imprinting.
↵∥ Normal lymphocytes were from individuals without evident malignancy.
↵¶ Fisher's exact P.